Inotiv
Contract research organization providing nonclinical and analytical drug discovery and preclinical development services. Capabilities include provision and support of research animal models (including cryopreserved and genetically engineered models), preclinical in vivo study design and execution, DMPK and bioanalysis, histology and pathology, targeted proteomics and assay development, custom research diet formulation and manufacture, monoclonal antibody production, and colony health and genetic monitoring.
Industries
Nr. of Employees
Very Large (1000+)
Inotiv
WEST LAFAYETTE, Indiana (press contact location)
Patents
Products
Purified and AIN research diet formulas
Controlled purified diet formulations and standard AIN formulas for rodent research with options for nutrient modification, irradiation and packaging to support reproducible preclinical studies.
Natural-ingredient laboratory animal diets
Natural-ingredient diet products formulated for breeding, growth and maintenance across multiple species, designed to minimize phytoestrogen and chlorophyll content for specific experimental and imaging applications; available in certified and irradiated formats.
Research animal model catalog (inbred, immunodeficient, engineered, cryopreserved)
Catalog of available research models including inbred strains, immunodeficient lines, knockout and transgenic rodents and cryopreserved lines available for order and recovery.
Purified and AIN research diet formulas
Controlled purified diet formulations and standard AIN formulas for rodent research with options for nutrient modification, irradiation and packaging to support reproducible preclinical studies.
Natural-ingredient laboratory animal diets
Natural-ingredient diet products formulated for breeding, growth and maintenance across multiple species, designed to minimize phytoestrogen and chlorophyll content for specific experimental and imaging applications; available in certified and irradiated formats.
Research animal model catalog (inbred, immunodeficient, engineered, cryopreserved)
Catalog of available research models including inbred strains, immunodeficient lines, knockout and transgenic rodents and cryopreserved lines available for order and recovery.
Services
Design and execution of nonclinical toxicology, safety, PK/PD and efficacy studies across discovery and preclinical development.
Provision of inbred, immunodeficient and genetically engineered models, contract breeding, timed‑mated production, surgical support and model preparation services.
Flexible small‑ and large‑scale monoclonal antibody production to supply research reagents and development materials.
Tissue processing, histochemistry, IHC, IF, ISH, stereology and pathology interpretation, with digital imaging and quantitative analysis options.
In vitro and in vivo DMPK studies, LC‑MS/MS bioanalysis and targeted proteomics for PK/PD and biomarker assessment.
Formulation and manufacture of purified, natural‑ingredient and standard research diets with irradiation, packaging and certification options and nutritionist consultation.
Design and execution of nonclinical toxicology, safety, PK/PD and efficacy studies across discovery and preclinical development.
Provision of inbred, immunodeficient and genetically engineered models, contract breeding, timed‑mated production, surgical support and model preparation services.
Flexible small‑ and large‑scale monoclonal antibody production to supply research reagents and development materials.
Tissue processing, histochemistry, IHC, IF, ISH, stereology and pathology interpretation, with digital imaging and quantitative analysis options.
In vitro and in vivo DMPK studies, LC‑MS/MS bioanalysis and targeted proteomics for PK/PD and biomarker assessment.
Formulation and manufacture of purified, natural‑ingredient and standard research diets with irradiation, packaging and certification options and nutritionist consultation.
Expertise Areas
- Preclinical in vivo model development and execution
- Genetically engineered models and colony management
- Nonclinical toxicology and safety assessment
- Drug metabolism, pharmacokinetics and bioanalysis (DMPK)
Key Technologies
- LC-MS/MS bioanalytical assays
- Targeted proteomics (mass spectrometry)
- Multiplex immunoassays (e.g., Luminex-style panels)
- Sandwich ELISA
News & Updates
Conference participation November 15-19, 2025 in San Diego, CA.
Conference participation November 16-19, 2025 in Phoenix, AZ.
Conference participation March 22-25, 2026 in San Diego, CA.
Press release describing amendment of the company's credit agreement and a private offering of second lien notes to increase liquidity and provide covenant relief through mid‑2025.
Ranked number 182 on the 2025 Deloitte Technology Fast 500 based on revenue growth from FY2021 to FY2024.
Conference participation November 15-19, 2025 in San Diego, CA.
Conference participation November 16-19, 2025 in Phoenix, AZ.
Conference participation March 22-25, 2026 in San Diego, CA.
Press release describing amendment of the company's credit agreement and a private offering of second lien notes to increase liquidity and provide covenant relief through mid‑2025.
Ranked number 182 on the 2025 Deloitte Technology Fast 500 based on revenue growth from FY2021 to FY2024.